S
SyntheX
Targeting the undruggable with synthetic biology-based drug discovery platforms
About SyntheX
SyntheX Labs operates in the biotechnology sector, focusing on drug discovery for previously undruggable proteins. Utilizing advanced genetics and synthetic biology, the company has developed proprietary platforms such as ToRPPIDO and ToRNeDO. These platforms use genetically engineered circuits for functional intracellular drug selection, which is more effective than traditional in vitro screening methods. SyntheX's technology allows for the discovery of novel compounds that can modulate protein interactions in unique ways, either orthosterically or allosterically. The primary clients include pharmaceutical companies and research institutions seeking innovative solutions for complex protein targets. SyntheX generates revenue through licensing its technology, partnerships, and collaborative research agreements. The company is positioned in the U.S. market but aims for global impact in the drug discovery landscape.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SyntheX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SyntheX on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



